Articles Tagged With: meropenem
-
Monotherapy of Pseudomonas aeruginosa Bacteremia — Which β-Lactam Antibiotic Is Best?
No significant difference in the mortality of patients with Pseudomonas aeruginosa bacteremia was seen regardless of treatment with a carbapenem, ceftazidime, or piperacillin-tazobactam. However, the emergence of resistance occurred significantly more frequently in those treated with a carbapenem — largely related to imipenem use.
-
Plazomicin (Zemdri)
Plazomicin is an aminoglycoside recently approved by the Food and Drug Administration for treating complicated urinary tract infections.
-
Meropenem vs. Piperacillin-tazobactam for Bacteremia Due to ESBL-Producers: The MERINO Trial
In an open-label, randomized, noninferiority trial evaluating the efficacy of piperacillin-tazobactam vs. meropenem for definitive therapy in treating bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae, piperacillin-tazobactam therapy did not result in noninferior 30-day, all-cause mortality compared to meropenem. Investigators stopped the trial early due to futility.
-
REPROVE: Ceftazidime-avibactam vs. Meropenem in Hospital-acquired Pneumonia
Ceftazidime-avibactam therapy was non-inferior to meropenem treatment in a double-blind, randomized trial that included patients with nosocomial pneumonia, including those with ventilator-associated pneumonia.
-
Meropenem-vaborbactam
Meropenem-vaborbactam (Vabomere) is the latest β-lactam/β-lactamase inhibitor (BLI), approved by the FDA in August 2017 for treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae species complex in adults older than 18 years of age.